Cargando…
Which Should Be Used First for ALK-Positive Non-Small-Cell Lung Cancer: Chemotherapy or Targeted Therapy? A Meta-Analysis of Five Randomized Trials
Background and objectives: Targeted therapy is widely used in the era of precision medicine. Whether the sequence in which targeted therapy and chemotherapy are performed matters, is however not known. We examined the impact of the sequential treatment of targeted therapy and chemotherapy among adva...
Autores principales: | Lee, Yen-Chien, Hsieh, Chung-Cheng, Lee, Yen-Ling, Li, Chung-Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409768/ https://www.ncbi.nlm.nih.gov/pubmed/30699985 http://dx.doi.org/10.3390/medicina55020029 |
Ejemplares similares
-
Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Cruz, Barbara D., et al.
Publicado: (2021) -
First-Line Anaplastic Lymphoma Kinase (ALK) Inhibitors for ALK-Positive Lung Cancer in Asian Populations: Systematic Review and Network Meta-Analysis
por: Wu, Kuan-Li, et al.
Publicado: (2021) -
Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer
por: Jo, Jaemin, et al.
Publicado: (2018) -
First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi, Shipra, et al.
Publicado: (2015) -
The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)